☆ 4.7 Article

Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan

SCIENTIFIC REPORTS (2023)

Related references

Note: Only part of the references are listed.

Article Neurosciences

Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study

Kadalraja Raghavan et al.

Summary: This study evaluates the effects of supplementation of Aureobasidium pullulans-N-163 strain produced 1,3-1,-6 beta glucan in young patients with Duchenne muscular dystrophy (DMD). The results showed that the N-163 beta glucan supplement could significantly decrease the levels of inflammation and fibrosis markers and improve muscle strength in DMD patients.

IBRO NEUROSCIENCE REPORTS (2023)

Add to Collection

Article Medicine, Research & Experimental

Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study

Kadalraja Raghavan et al.

Summary: This pilot clinical study demonstrated the beneficial effects of beta glucans derived from black yeast Aureobasidium pullulans on cytokine storm and coagulopathy biomarkers in COVID-19 patients. The combination of AFO-202 and N-163 beta glucans showed significant improvements in D-Dimer and IL-6 levels, as well as CD4+ and CD8+ T cell count. Larger multicentric clinical studies are recommended to further validate these findings for potential use in managing COVID-19 and long COVID-19 syndrome.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Article Endocrinology & Metabolism

Beneficial effects of 1,3-1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation

Nobunao Ikewaki et al.

Summary: This study compared the effects of two strains of Aureobasidium pullulans (AFO-202 and N-163) produced beta-glucans on lipotoxicity in an obese and diabetic mouse model. The results showed that N-163 beta-glucans had the lowest impact on non-esterified fatty acids (NEFA) levels and slightly decreased triglyceride levels compared to other groups. However, there were no significant differences in blood glucose, hemoglobin A1c (HbA1c), triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels. Further research is needed to explore the mechanisms of lipotoxicity and related inflammatory cascades for the prevention and management of metabolic dysregulation and associated diseases such as non-alcoholic fatty liver disease (NAFLD).

JOURNAL OF DIABETES AND METABOLIC DISORDERS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Hepatoprotective Effects of Aureobasidium pullulans Derived ? 1,3-1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis

Nobunao Ikewaki et al.

Summary: This study evaluated the potential of AFO-202 and N-163 beta-glucans as anti-fibrotic and anti-inflammatory hepatoprotective agents in a NASH animal model. The results showed that AFO-202 significantly reduced inflammation-associated hepatic cell ballooning and steatosis, while N-163 significantly decreased fibrosis and inflammation. The combination of AFO-202 with N-163 significantly decreased the NAFLD Activity Score.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease

Senthilkumar Preethy et al.

Summary: The study showed a significant increase in gut microbial diversity in the AFO-202+N-163 group, along with changes in beneficial faecal metabolites, indicating potential benefits for both the nervous system and metabolic conditions.

BMJ OPEN GASTROENTEROLOGY (2022)

Add to Collection

Review Oncology

Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy

Anna Rugowska et al.

Summary: Duchenne muscular dystrophy is a multisystem disorder that predominantly affects boys, caused by mutations in the DMD gene leading to changes in dystrophin expression profile. Loss of dystrophin results in muscle fiber disintegration and impaired regeneration, with associations to the loss of neuronal nitric oxide synthase.

CLINICAL EPIGENETICS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration

Ankita Tulangekar et al.

Summary: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder caused by mutations in the dystrophin gene. Lack of functional dystrophin protein leads to fragile muscle membranes and increased susceptibility to damage during contraction. Inflammation plays a crucial role in exacerbating muscle damage and impairing regeneration in DMD patients, with neutrophils releasing inflammatory compounds that prolong the inflammatory response.

BIOMEDICINES (2021)

Add to Collection

Review Cell Biology

Current Pharmacological Strategies for Duchenne Muscular Dystrophy

Shanshan Yao et al.

Summary: Duchenne muscular dystrophy is a lethal neuromuscular disorder caused by the absence of dystrophin protein, with no cure currently available. The standard of care involves glucocorticoids treatments for symptom relief. Therapeutic strategies focus on restoring dystrophin function and targeting downstream pathological changes like inflammation and fibrosis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Public, Environmental & Occupational Health

Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis

Erik Landfeldt et al.

EUROPEAN JOURNAL OF EPIDEMIOLOGY (2020)

Add to Collection

Review Genetics & Heredity

Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis

Salvatore Crisafulli et al.

ORPHANET JOURNAL OF RARE DISEASES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy

Samara Camacari de Carvalho et al.

CYTOKINE (2018)

Add to Collection

Article Medicine, Research & Experimental

Long-Term Morpholino Oligomers in Hexose Elicits Long-Lasting Therapeutic Improvements in mdx Mice

Gang Han et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2018)

Add to Collection

Article Medicine, Research & Experimental

Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy

Sandra Murphy et al.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)

Add to Collection

Article Clinical Neurology

Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents

Alan S. Robertson et al.

NEUROMUSCULAR DISORDERS (2017)

Add to Collection

Article Pathology

Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy

Michel. Abou-Samra et al.

AMERICAN JOURNAL OF PATHOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background

Merryl Rodrigues et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

Article Orthopedics

Dystrophin and utrophin double knockout dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities

Christian Isaac et al.

JOURNAL OF ORTHOPAEDIC RESEARCH (2013)

Add to Collection

Article Multidisciplinary Sciences

Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse

Jonathon M. Tinsley et al.

PLOS ONE (2011)

Add to Collection

Article Biochemistry & Molecular Biology

Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice

Kaori Ito et al.

HUMAN MOLECULAR GENETICS (2006)

Add to Collection

Article Hematology

Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression

E Lutgens et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)

Add to Collection

Article Pathology

Resolution of skeletal muscle inflammation in mdx dystrophic mouse is accompanied by increased immunoglobulin and interferon-γ production

J Lagrota-Candido et al.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.